.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Colorcon
UBS
AstraZeneca
Argus Health
US Army
Teva
Dow
Express Scripts
US Department of Justice

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203049

« Back to Dashboard
NDA 203049 describes ARGATROBAN, which is a drug marketed by Fresenius Kabi Usa, Hospira Inc, Mylan Institutional, Hikma Pharm Co Ltd, Par Sterile Products, Novartis Pharms Corp, Teva Pharms Usa, Sandoz, Eagle Pharms, and Gland Pharma Ltd, and is included in eleven NDAs. It is available from five suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ARGATROBAN profile page.

The generic ingredient in ARGATROBAN is argatroban. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the argatroban profile page.

Summary for 203049

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 203049

Mechanism of ActionThrombin Inhibitors

Suppliers and Packaging for NDA: 203049

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ARGATROBAN
argatroban
INJECTABLE;INJECTION 203049 NDA West-Ward Pharmaceuticals Corp 0143-9288 0143-9288-01 1 VIAL in 1 CARTON (0143-9288-01) > 2.5 mL in 1 VIAL
ARGATROBAN
argatroban
INJECTABLE;INJECTION 203049 NDA West-Ward Pharmaceuticals Corp 0143-9559 0143-9559-01 1 VIAL in 1 CARTON (0143-9559-01) > 50 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength250MG/2.5ML (100MG/ML)
Approval Date:Jan 5, 2012TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength50MG/50ML (1MG/ML)
Approval Date:Sep 30, 2016TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
US Department of Justice
Merck
Julphar
Express Scripts
Queensland Health
Johnson and Johnson
Federal Trade Commission
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot